Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

Novo Nordisk reported Q4 sales of $11.96 billion, beating estimates. The company plans a new phase 3 trial for CagriSema in ...

Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

The future of GLP-1 drugs is looking bigger than anyone predicted. As governments consider broader adoption and competitors scramble to keep up, Novo Nordisk is well-positioned to lead this ...

LONDON/COPENHAGEN (Reuters) -Novo Nordisk defended its next-generation ... Lilly emerges as a strong competitor in the biggest market for obesity drugs, the United States. Novo plans to begin ...

The rest, as they say, is history. Ozempic and Wegovy are now two of the biggest blockbuster drugs on the market. The two drugs are Novo Nordisk's top growth drivers, and together comprise over 60 ...